Literature DB >> 19538055

Early changes in 2-deoxy-2-[18F]fluoro-D-glucose metabolism in squamous-cell carcinoma during chemotherapy in vivo and in vitro.

Maria Bjurberg1, Eva Henriksson, Eva Brun, Lars Ekblad, Tomas Ohlsson, Arne Brun, Elisabeth Kjellén.   

Abstract

AIM: The aim of this study was to investigate early changes in uptake of 2-deoxy-2-[(18)F]fluoro-D-glucose (FDG) in vivo and in vitro in a squamous-cell carcinoma (SCC) cell line originating from a human head and neck SCC during cytotoxic therapy with respect to metabolism in tumor cells and in surrounding stromal tissue.
MATERIALS AND METHODS: In 60 nude mice with xenografted SCC, 50 animals were treated with cisplatin. Early changes in the tumor FDG uptake following therapy were evaluated sequentially with phosphor imaging. Using this technique, areas with focal hypermetabolism were detected. The cells creating the focal hypermetabolism were then identified histopathologically on the corresponding sections. In addition, early FDG uptake versus the number of viable tumor cells was measured in vitro following cisplatin treatment.
RESULTS: An early transient increase in FDG uptake in tumor cells was seen on day 1 in treated tumors, followed by a rapid decrease confirmed by subsequent tumor regression. This metabolic flare was present in all treated tumors but not in the controls. In vitro, an increase in FDG uptake per cell was observed.
CONCLUSIONS: Our results provide new insights into the early metabolic changes in squamous-cell carcinomas subjected to cytotoxic therapy and thus contribute to the discussion on the feasibility of early predictive PET studies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19538055     DOI: 10.1089/cbr.2008.0556

Source DB:  PubMed          Journal:  Cancer Biother Radiopharm        ISSN: 1084-9785            Impact factor:   3.099


  12 in total

1.  [18F]fluoromethylcholine as a chemotherapy response read-out in prostate cancer cells.

Authors:  Daniela E Oprea-Lager; Mitchell P van Kanten; Reindert J A van Moorselaar; Alfons J M van den Eertwegh; Peter M van de Ven; Irene V Bijnsdorp; Otto S Hoekstra; Albert A Geldof
Journal:  Mol Imaging Biol       Date:  2015-06       Impact factor: 3.488

2.  Early prediction of survival following induction chemotherapy with DCF (docetaxel, cisplatin, 5-fluorouracil) using FDG PET/CT imaging in patients with locally advanced head and neck squamous cell carcinoma.

Authors:  Ronan Abgral; Pierre-Yves Le Roux; Nathalie Keromnes; Jean Rousset; Gérald Valette; Dominique Gouders; Cyril Leleu; Delphine Mollon; Emmanuel Nowak; Solène Querellou; Pierre-Yves Salaün
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-08-16       Impact factor: 9.236

3.  Integrin α(v)β₃ as a PET imaging biomarker for osteoclast number in mouse models of negative and positive osteoclast regulation.

Authors:  Alexander Zheleznyak; Thaddeus J Wadas; Christopher D Sherman; Jessica M Wilson; Paul J Kostenuik; Katherine N Weilbaecher; Carolyn J Anderson
Journal:  Mol Imaging Biol       Date:  2012-08       Impact factor: 3.488

4.  Optical imaging of breast cancer oxyhemoglobin flare correlates with neoadjuvant chemotherapy response one day after starting treatment.

Authors:  Darren Roblyer; Shigeto Ueda; Albert Cerussi; Wendy Tanamai; Amanda Durkin; Rita Mehta; David Hsiang; John A Butler; Christine McLaren; Wen-Pin Chen; Bruce Tromberg
Journal:  Proc Natl Acad Sci U S A       Date:  2011-08-18       Impact factor: 11.205

5.  Sequential FDG-PET/CT after neoadjuvant chemotherapy is a predictor of histopathologic response in patients with head and neck squamous cell carcinoma.

Authors:  Masahiro Kikuchi; Shogo Shinohara; Yuji Nakamoto; Yu Usami; Keizo Fujiwara; Tsunemichi Adachi; Shin-ya Hori; Yosuke Tona; Hiroshi Yamazaki; Yukihiro Imai; Yasushi Naito
Journal:  Mol Imaging Biol       Date:  2011-04       Impact factor: 3.488

6.  Utility of 3'-[(18)F]fluoro-3'-deoxythymidine as a PET tracer to monitor response to gene therapy in a xenograft model of head and neck carcinoma.

Authors:  Neale S Mason; Brian J Lopresti; James Ruszkiewicz; Xinxin Dong; Sonali Joyce; George Leef; Malabika Sen; Abdus S Wahed; Chester A Mathis; Jennifer R Grandis; Sufi M Thomas
Journal:  Am J Nucl Med Mol Imaging       Date:  2013-01-05

7.  Early Metabolic Flare in Squamous Cell Carcinoma after Chemotherapy is a Marker of Treatment Sensitivity In Vitro.

Authors:  Maria Bjurberg; Parisa Abedinpour; Eva Brun; Bo Baldetorp; Per Borgström; Johan Wennerberg; Elisabeth Kjellén
Journal:  Nucl Med Mol Imaging       Date:  2010-06-09

8.  [¹⁸F]FDG positron emission tomography within two weeks of starting erlotinib therapy can predict response in non-small cell lung cancer patients.

Authors:  Mammar Hachemi; Olivier Couturier; Laurent Vervueren; Pacôme Fosse; Franck Lacœuille; Thierry Urban; José Hureaux
Journal:  PLoS One       Date:  2014-02-05       Impact factor: 3.240

9.  Chemotherapy with cisplatin: insights into intracellular pH and metabolic landscape of cancer cells in vitro and in vivo.

Authors:  Marina V Shirmanova; Irina N Druzhkova; Maria M Lukina; Varvara V Dudenkova; Nadezhda I Ignatova; Ludmila B Snopova; Vladislav I Shcheslavskiy; Vsevolod V Belousov; Elena V Zagaynova
Journal:  Sci Rep       Date:  2017-08-21       Impact factor: 4.379

Review 10.  Effectiveness of FDG-PET/CT for evaluating early response to induction chemotherapy in head and neck squamous cell carcinoma: A systematic review.

Authors:  Renata Fockink Dos Anjos; Dalton Alexandre Dos Anjos; Danielle Leal Vieira; André Ferreira Leite; Paulo Tadeu de Souza Figueiredo; Nilce Santos de Melo
Journal:  Medicine (Baltimore)       Date:  2016-08       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.